RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?

2026-02-28 15:34:48

Abstract generation in progress

Rigel Pharmaceuticals (RIGL) stock has significantly outperformed its industry, sector, and the S&P 500 over the past year, driven by strong performance from its marketed product Tavalisse and growing contributions from its oncology drugs. The company reported robust preliminary financial results for Q4 and full-year 2025 and projects continued growth in 2026, aiming for positive net income. Despite competitive threats from larger pharmaceutical companies, Rigel’s pipeline and positive analyst outlook suggest growth potential, leading to a Zacks Rank #3 (Hold) recommendation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.